Stocktoria
Nkarta, Inc. NKTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-07-10
Nkarta, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | $0 | — | $115,000 |
| R&D expense | $90.4M | $96.7M | $96.8M | $90.9M | $63.4M | $36.2M | $17.2M |
| Operating income | -$122.0M | -$128.2M | -$131.7M | -$119.0M | -$86.4M | -$51.5M | -$22.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$104.1M | -$108.8M | -$117.5M | -$113.8M | -$86.1M | -$91.4M | -$21.1M |
| EPS (diluted) | $-1.41 | $-1.60 | $-2.40 | $-2.61 | $-2.62 | — | — |
| Operating cash flow | -$88.7M | -$99.7M | -$86.2M | -$57.0M | -$67.9M | -$43.5M | -$18.4M |
| Free cash flow | -$89.9M | -$104.1M | -$114.3M | -$104.1M | -$73.0M | -$51.0M | -$20.3M |
| Cash & equivalents | $39.6M | $27.9M | $31.0M | $37.5M | $60.8M | $96.7M | $20.6M |
| Total assets | $404.2M | $501.2M | $378.9M | $472.9M | $273.9M | $337.6M | $48.4M |
| Total liabilities | $91.9M | $93.2M | $105.6M | $100.7M | $22.9M | $16.4M | $14.1M |
| Shareholders' equity | $312.3M | $408.0M | $273.3M | $372.2M | $251.0M | $321.2M | -$25.5M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.